New Drug Targets Epigenetic Mark, May Help Treat Rare Cancer
In 2020, the FDA approved Epizyme’s drug tazemetostat (Brand name: Tazverik) to treat a rare type of solid tumor called epithelioid sarcoma. Tazemetostat targets the epigenetic enzyme EZH2, which is strongly linked to several cancer types. Now, Epizyme is seeking accelerated approval for tazemetostat to treat a common form of blood cancer called follicular lymphoma, and has clinical trials running for several additional cancer types. Cancer is a genetic disease that causes unrestrained cell proliferation. Typically, chemotherapies treat cancer by [more…]
